Sugi Predict

Sugi Predict / Compounds / SCHEMBL3926899

SCHEMBL3926899

SCHEMBL3926899

O=C(Nc1nc2ccccc2[nH]1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 14/20 1.00
▸ RAB9A P51151 14/20 1.00
▸ PKM P14618 5/20 1.00
▸ SMN1; SMN2 Q16637 3/20 1.00
▸ MAOB P27338 1/20 1.00
▸ ADORA2A P29274 1/20 1.00
▸ SCD O00767 1/20 0.89
▸ KLF5 Q13887 2/20 0.78
▸ OPRK1 P41145 1/20 0.78
▸ KDM4E B2RXH2 1/20 0.78
▸ TP53 P04637 1/20 0.78
▸ HSD17B10 Q99714 1/20 0.78
▸ MEN1 O00255 6/20 0.72
▸ KMT2A Q03164 6/20 0.72
▸ MAPT P10636 1/20 0.71
▸ IRAK4 Q9NWZ3 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11703736 0.95 NPC1 (0.91) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11707899 0.94 SCD (1.00) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11706930 0.92 NPC1 (0.86) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11705316 0.91 NPC1 (0.83) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11703862 0.91 NPC1 (0.83) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11706324 0.89 NPC1 (0.81) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11705932 0.89 NPC1 (0.81) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11703126 0.89 NPC1 (0.79) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL16562173 0.88 NPC1 (0.78) NPC1RAB9APKMSMN1; SMN2MAOB
SCHEMBL11702938 0.88 NPC1 (0.80) NPC1RAB9APKMSMN1; SMN2MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110965064-B Application of alkylamide benzimidazole compound, organic weldable protective agent, preparation method, use method and application thereof 深圳市贝加电子材料有限公司 2022-04-29 — — CN claimed
CN-110965064-A Application of alkylamide benzimidazole compound, organic weldable protective agent, preparation method, use method and application thereof 深圳市贝加电子材料有限公司 2020-04-07 — — CN claimed
JP-2003508382-A — — 2003-03-04 — — JP claimed
EP-1212296-A1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS Sugen, Inc. (US) 2002-06-12 — — EP claimed
WO-2001016097-A1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN, INC. (US) 2001-03-08 — — WO claimed
EP-0358749-A1 1,4-SUBSTITUTED-2,3,5,6-TETRAHYDRO 1,3,6]TRIAZOCINO 1,2-a]BENZIMIDAZOLES AND INTERMEDIATES THEREFOR AMERICAN HOME PRODUCTS CORPORATION (US) 1990-03-21 — — EP claimed
WO-1989008111-A1 1,4-SUBSTITUTED-2,3,5,6-TETRAHYDRO[1,3,6]TRIAZOCINO[1,2-a]BENZIMIDAZOLES AND INTERMEDIATES THEREFOR AMERICAN HOME PRODUCTS CORPORATION (US) 1989-09-08 — — WO claimed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
WO-2023192586-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
EP-0361069-A1 Benzimidazole-2-carboxylic-acid anilides, their use as photoprotection composition for organic materials and organic materials stabilised by these anilides BASF Aktiengesellschaft (DE) 1990-04-04 — — EP disclosed
EP-0358025-A1 N-substituted benzimidazole-2-carboxylic-acid anilides, their photoprotection compositions, particularly polymers, and organic material containing these anilides BASF Aktiengesellschaft (DE) 1990-03-14 — — EP disclosed
US-4882323-A ANTIARRYTHMIA AGENT INTERMEDIATES AMERICAN HOME PRODUCTS (US) 1989-11-21 — — US disclosed
US-4011236-A N-(BENZIMIDAZOL-2-YL)ARYLCARBOXAMIDES AS ULTRAVIOLET (UV) LIGHT ABSORBERS MERCK & CO., INC. (US) 1977-03-08 — — US disclosed
US-4009164-A Novel 2-substituted-1,2,4-thiadiazole-[2,3-a]-benzimidazoles and process for their preparation SYNTEX (U.S.A.) INC. (US) 1977-02-22 — — US disclosed
US-3976654-A FUNGICIDE SYNTEX (U.S.A.) INC. (US) 1976-08-24 — — US disclosed
US-3946031-A FUNGICIDES SYNTEX INC. (US) 1976-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NPC1 3159/4885RAB9A 4270/4885PKM 1372/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 NPC1 3159/4885RAB9A 4270/4885PKM 1372/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NPC1 3159/4885RAB9A 4270/4885PKM 1372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.